These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 32516028)

  • 21. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD.
    Pierantonelli I; Rychlicki C; Agostinelli L; Giordano DM; Gaggini M; Fraumene C; Saponaro C; Manghina V; Sartini L; Mingarelli E; Pinto C; Buzzigoli E; Trozzi L; Giordano A; Marzioni M; Minicis S; Uzzau S; Cinti S; Gastaldelli A; Svegliati-Baroni G
    Sci Rep; 2017 Sep; 7(1):12200. PubMed ID: 28939830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NOD2 Influences Trajectories of Intestinal Microbiota Recovery After Antibiotic Perturbation.
    Moltzau Anderson J; Lipinski S; Sommer F; Pan WH; Boulard O; Rehman A; Falk-Paulsen M; Stengel ST; Aden K; Häsler R; Bharti R; Künzel S; Baines JF; Chamaillard M; Rosenstiel P
    Cell Mol Gastroenterol Hepatol; 2020; 10(2):365-389. PubMed ID: 32289499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease.
    Fei N; Bruneau A; Zhang X; Wang R; Wang J; Rabot S; Gérard P; Zhao L
    mBio; 2020 Feb; 11(1):. PubMed ID: 32019793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation.
    Chen L; Kan J; Zheng N; Li B; Hong Y; Yan J; Tao X; Wu G; Ma J; Zhu W; Sheng L; Chen L; Li B; Zhong J; Du J; Li H
    Phytomedicine; 2021 Oct; 91():153693. PubMed ID: 34403877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
    Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
    Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tectorigenin ameliorated high-fat diet-induced nonalcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in mice.
    Duan R; Huang K; Guan X; Li S; Xia J; Shen M; Sun Z; Yu Z
    Food Chem Toxicol; 2022 Jun; 164():112948. PubMed ID: 35390440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
    Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
    World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.
    Quesada-Vázquez S; Aragonès G; Del Bas JM; Escoté X
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.
    Petrov PD; García-Mediavilla MV; Guzmán C; Porras D; Nistal E; Martínez-Flórez S; Castell JV; González-Gallego J; Sánchez-Campos S; Jover R
    Mol Nutr Food Res; 2019 Oct; 63(20):e1900487. PubMed ID: 31322321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.
    Panasevich MR; Peppler WT; Oerther DB; Wright DC; Rector RS
    Physiol Genomics; 2017 Aug; 49(8):385-399. PubMed ID: 28600319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
    Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
    Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Western diet-induced mouse model of non-alcoholic fatty liver disease associated with metabolic outcomes: Features of gut microbiome-liver-adipose tissue axis.
    Romualdo GR; Valente LC; Sprocatti AC; Bacil GP; de Souza IP; Rodrigues J; Rodrigues MAM; Vinken M; Cogliati B; Barbisan LF
    Nutrition; 2022; 103-104():111836. PubMed ID: 36202025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SIRT2 Deficiency Aggravates Diet-Induced Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites.
    Li X; Du Y; Xue C; Kang X; Sun C; Peng H; Fang L; Han Y; Xu X; Zhao C
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
    Bozic M; Guzmán C; Benet M; Sánchez-Campos S; García-Monzón C; Gari E; Gatius S; Valdivielso JM; Jover R
    J Hepatol; 2016 Oct; 65(4):748-757. PubMed ID: 27245430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
    Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P
    Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.
    Schneider KM; Mohs A; Kilic K; Candels LS; Elfers C; Bennek E; Schneider LB; Heymann F; Gassler N; Penders J; Trautwein C
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
    Wang W; Zhao J; Gui W; Sun D; Dai H; Xiao L; Chu H; Du F; Zhu Q; Schnabl B; Huang K; Yang L; Hou X
    Br J Pharmacol; 2018 Feb; 175(3):469-484. PubMed ID: 29139555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A rise in Proteobacteria is an indicator of gut-liver axis-mediated nonalcoholic fatty liver disease in high-fructose-fed adult mice.
    Vasques-Monteiro IML; Silva-Veiga FM; Miranda CS; de Andrade Gonçalves ÉCB; Daleprane JB; Souza-Mello V
    Nutr Res; 2021 Jul; 91():26-35. PubMed ID: 34130208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice.
    Moreira GV; Azevedo FF; Ribeiro LM; Santos A; Guadagnini D; Gama P; Liberti EA; Saad M; Carvalho C
    J Nutr Biochem; 2018 Dec; 62():143-154. PubMed ID: 30292107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of the gut microbiota in NAFLD.
    Leung C; Rivera L; Furness JB; Angus PW
    Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.